FDA Launches Public Input Process for BsUFA IV Reauthorization to Shape Biosimilar Regulatory Framework Through 2032
Key Insights
The FDA has announced plans to seek public input on the reauthorization of the Biosimilar User Fee Act (search) (BsUFA IV (search)) covering fiscal years 2028-2032, with the current authority expiring in September 2027.
The agency will hold a public meeting on December 3, 2025, and accept written comments until January 2, 2026, to gather stakeholder feedback on fee structures, performance goals, and regulatory efficiency enhancements.
BsUFA, originally enacted in 2012 and renewed twice, provides FDA with additional resources including staffing to ensure efficient and predictable biosimilar (search) application reviews.
The U.S. Food and Drug Administration has initiated the public input process for the reauthorization of the Biosimilar User Fee Act (search) (BsUFA IV (search)), which will govern the agency's biosimilar (search) regulatory framework from fiscal years 2028 through 2032. The announcement comes as the current BsUFA III authority approaches its September 2027 expiration date, requiring new legislation for the FDA to continue collecting user fees that support biosimilar product reviews.
Comprehensive Stakeholder Engagement Strategy
The FDA is implementing a multi-faceted approach to gather stakeholder feedback, including a public meeting scheduled for December 3, 2025, from 9 a.m. to 12 p.m. EST. The meeting will be held both in-person at FDA's White Oak Campus and virtually to maximize participation. Following the meeting, the agency will continue accepting written comments through a public docket until January 2, 2026.
The FDA is specifically seeking input from industry representatives, healthcare professionals, and patient advocacy groups on various aspects of the program. Key areas of focus include fee structures, performance goals, and enhancements to regulatory efficiency that could better address challenges in biosimilar (search) development and approval.
Evolution of the BsUFA Program
Since its original enactment in 2012, BsUFA has undergone two reauthorizations, with each iteration building upon previous successes while addressing emerging needs in the biosimilar (search) landscape. The program is designed to provide FDA with additional resources, particularly staffing, to ensure efficient and predictable biosimilar application reviews.
Under each reauthorization, the FDA and industry establish specific performance goals and procedures, including defined timelines for reviewing applications and commitments related to meetings, communication practices, and regulatory science efforts. The current BsUFA III includes several enhancements such as new supplement categories, updated review timelines, expanded support for interchangeable biosimilars, improved inspection communication, and significant investments in IT and data modernization.
Key Areas for Stakeholder Input
The FDA is particularly interested in feedback regarding the performance of the current BsUFA program, seeking guidance on which elements should be maintained, modified, or discontinued. The agency is also exploring whether new components should be added to the framework and whether the current fee structure requires updates to better support biosimilar (search) development and ensure timely patient access.
This comprehensive review process reflects the FDA's commitment to refining its biosimilar (search) regulatory approach based on real-world experience and stakeholder needs. The agency plans to use the collected feedback to inform negotiations with industry representatives before finalizing recommendations for Congress.
Transparency and Accessibility
To ensure transparency throughout the process, the FDA has committed to posting a transcript of the December meeting and all submitted comments online once they become available. This approach allows for broader stakeholder awareness of the discussions and considerations shaping the future of biosimilar (search) regulation.
The reauthorization process represents a critical opportunity for stakeholders to influence the regulatory framework that will govern biosimilar (search) development and approval for the next five years, potentially impacting patient access to these important therapeutic alternatives.